Behavioral therapy combined with stimulants is more effective and tolerable than other treatments for attention-deficit/hyperactivity disorder (ADHD), according to a recently published review and network meta-analysis of 190 randomized trials. The review did not find evidence to support cognitive training, neurofeedback, antidepressants, antipsychotics, dietary therapy, fatty acids, and other complementary and alternative medicine.
Behavioral therapy combined with stimulants is more effective and tolerable than other treatments for attention-deficit/hyperactivity disorder (ADHD), according to a recently published review and network meta-analysis of 190 randomized trials.
The researchers compared the efficacy and safety of medications, psychological and complementary and alternative medicine interventions for the treatment of ADHD in children and adolescents. The trials involved 26,114 participants.
Poor quality of care for pediatric ADHD care can lead to increased healthcare costs as adults, and this latest report, published in PLoS ONE, noted that many caregivers often turn to complementary and alternative medicine to try and control ADHD symptoms. The researchers noted that due to the lack of head-to-head trials, the comparative efficacy of drug and nondrug interventions is not known. However, this review found a lack of evidence for cognitive training, neurofeedback, antidepressants, antipsychotics, dietary therapy, fatty acids, and other complementary and alternative medicine.
They found that any intervention—behavioral therapy (alone or in combination with stimulants), stimulants, and non-stimulant—seemed significantly more effective than placebo. Other findings included:
While the medications were linked to some side effects (anorexia, weight loss and insomnia), an increased risk of serious adverse events was not observed.
The researchers noted that there is urgent need for high-quality randomized trials of the multiple treatments for ADHD in children and adolescents, and that before starting any treatment the risks and benefits need to be weighed.
Of their review, researchers wrote that their overall findings were limited by the clinical and methodological heterogeneity, small sample sizes of trials, short-term follow-up, and the absence of high-quality evidence.
Reference
Catalá-López F, Hutton B, Núñez-Beltrán A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7). doi.org/10.1371/journal.pone.0180355. Published July 12, 2017. Accessed December 18, 2017.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More